Show simple item record

dc.contributor.authorClemente-Moragón, Agustín
dc.contributor.authorMartínez-Milla, Juan
dc.contributor.authorOliver, Eduardo 
dc.contributor.authorSantos, Arnoldo 
dc.contributor.authorFlandes, Javier
dc.contributor.authorFernández, Iker
dc.contributor.authorRodríguez-González, Lorena
dc.contributor.authorSerrano Del Castillo, Cristina
dc.contributor.authorIoan, Ana-María
dc.contributor.authorLópez-Álvarez, María
dc.contributor.authorGómez-Talavera, Sandra
dc.contributor.authorGalán-Arriola, Carlos
dc.contributor.authorFuster, Valentin 
dc.contributor.authorPérez-Calvo, César
dc.contributor.authorIbáñez, Borja 
dc.date.accessioned2023-07-06T10:13:10Z
dc.date.available2023-07-06T10:13:10Z
dc.date.issued2021-09-07
dc.identifier.citationJ Am Coll Cardiol. 2021 Sep 7;78(10):1001-1011es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16212
dc.description.abstractSevere coronavirus disease-2019 (COVID-19) can progress to an acute respiratory distress syndrome (ARDS), which involves alveolar infiltration by activated neutrophils. The beta-blocker metoprolol has been shown to ameliorate exacerbated inflammation in the myocardial infarction setting. The purpose of this study was to evaluate the effects of metoprolol on alveolar inflammation and on respiratory function in patients with COVID-19-associated ARDS. A total of 20 COVID-19 patients with ARDS on invasive mechanical ventilation were randomized to metoprolol (15 mg daily for 3 days) or control (no treatment). All patients underwent bronchoalveolar lavage (BAL) before and after metoprolol/control. The safety of metoprolol administration was evaluated by invasive hemodynamic and electrocardiogram monitoring and echocardiography. Metoprolol administration was without side effects. At baseline, neutrophil content in BAL did not differ between groups. Conversely, patients randomized to metoprolol had significantly fewer neutrophils in BAL on day 4 (median: 14.3 neutrophils/µl [Q1, Q3: 4.63, 265 neutrophils/µl] vs median: 397 neutrophils/µl [Q1, Q3: 222, 1,346 neutrophils/µl] in the metoprolol and control groups, respectively; P = 0.016). Metoprolol also reduced neutrophil extracellular traps content and other markers of lung inflammation. Oxygenation (PaO2:FiO2) significantly improved after 3 days of metoprolol treatment (median: 130 [Q1, Q3: 110, 162] vs median: 267 [Q1, Q3: 199, 298] at baseline and day 4, respectively; P = 0.003), whereas it remained unchanged in control subjects. Metoprolol-treated patients spent fewer days on invasive mechanical ventilation than those in the control group (15.5 ± 7.6 vs 21.9 ± 12.6 days; P = 0.17). In this pilot trial, intravenous metoprolol administration to patients with COVID-19-associated ARDS was safe, reduced exacerbated lung inflammation, and improved oxygenation. Repurposing metoprolol for COVID-19-associated ARDS appears to be a safe and inexpensive strategy that can alleviate the burden of the COVID-19 pandemic.es_ES
dc.description.sponsorshipMr Clemente-Moragón is supported by a fellowship from the Ministerio de Ciencia e Innovación (FPU2017/01932). The CNIC is supported by the ISCIII, the Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation. Dr Ibáñez is supported by the European Commission (ERC-CoG grant No 819775) and by the Spanish Ministry of Science and Innovation (MCN; “RETOS 2019” grant No PID2019- 107332RB-I00). Dr Oliver is supported by funds from the Comunidad de Madrid Programa de Atracción de Talento (2017-T1/BMD-5185). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.es_ES
dc.language.isoenges_ES
dc.publisherElsevier es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshPandemics es_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshAdrenergic beta-1 Receptor Antagonists es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshCritical Illness es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInjections, Intravenous es_ES
dc.subject.meshMale es_ES
dc.subject.meshMetoprolol es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshPilot Projects es_ES
dc.subject.meshProspective Studies es_ES
dc.subject.meshRespiration, Artificial es_ES
dc.titleMetoprolol in Critically Ill Patients With COVID-19.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID34474731es_ES
dc.format.volume78es_ES
dc.format.number10es_ES
dc.format.page1001es_ES
dc.identifier.doi10.1016/j.jacc.2021.07.003es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderFundación ProCNIC es_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1558-3597es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.jacc.2021.07.003es_ES
dc.identifier.journalJournal of the American College of Cardiologyes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/ERC/CoG/819775es_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU2017/01932es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-107332RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2017-T1/BMD-5185es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional